Fig. 3
From: p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
EGFR inhibition does not affect cell viability of NSCLC cell lines and tumor-derived primary cells with mutations along the EGFR/RAS/MAPK pathway. Dose-response curves of a human NSCLC cell lines (SK-Lu1, Calu-6, NCI-H1975 and NCI-H2228) and b primary lung cancer cell lines derived from KrasLSL-G12D (LSZ1, LKR13) and KrasLSL-G12D;Trp53f/f mice, (389 N1, 482 N1) treated with increasing concentrations of EGFR inhibitors (Erlotinib and Gefitinib). Cell viability was evaluated by MTT assay. X-axis crosses in correspondence of T0 values (before starting the treatment); 72 h values are then expressed as the variation relative to the initial cell number. Scale on Y-axis is adapted to the different growth rates shown by each cell line. Data are presented as mean ± SEM. n ≥ 3 independent experiments